Moderately severe osteogenesis imperfecta associated with substitutions of serine for glycine in the α1(I) chain of type I collagen
- 15 January 1993
- journal article
- case report
- Published by Wiley in American Journal of Medical Genetics
- Vol. 45 (2) , 241-245
- https://doi.org/10.1002/ajmg.1320450217
Abstract
We have examined the type I collagen protein, RNA, and cDNA of 2 children with moderately severe (type IV) osteogenesis imperfecta (OI). They have in common a non‐lethal form of OI with ambulatory potential, over‐modification of type I collagen protein, and a substitution of serine for glycine in the collagen chain produced by one α1(I) allele. The first child (Marini et al.: J Biol Chem 264:11893‐11900, 1989) is now 7 years old, with the height of a 3‐year‐old. Her course includes significant remodeling of lower long bones and 4 femur fractures. She walks independently. A mishmatch was detected in her α1(I) mRNA using RNA/RNA hybrids; it was demonstrated to be due to a G→A point mutation in one allele of α1(I), resulting in the substitution of serine for glycine 832. The second child is now 6½ years old, with the height of 1½‐year‐old. Her history includes significant bowing of femurs and tibias, 6 femur fractures, S‐curve scoliosis, compression of all lumbar vertebrae, and limited short‐distance walking with braces. Her α1(I) mRNA has also been studied by RNA hybrid analysis; there is a single G→A change in one α1(I) allele causing the substitution of serine for gly 352. Both children have moderately severe OI. However, the serine substitution at gly 352 is associated with a more severe phenotype then is the serine substitution at gly 832. Compared to substitutions described in other cases of OI, the serine 352 is located in the middle of a cluster of cysteine substitutions associated with non‐lethal OI. The ser 832 is located near another non‐lethal substitution of serine for glycine but is otherwise flanked by lethal sub‐stitutions. These data support a model of OI cause in which crucial and non‐crucial regions are interspersed along the type I collagen chain. Whether a mutation located in a particular region causes OI type II or OI type IV would then depend on the importance of that region for the interaction of type I collagen with other matrix components or for intracellular processing.Keywords
This publication has 4 references indexed in Scilit:
- Anomalous Cysteine in Type I Collagen. Localisation by Chemical Cleavage of the Protein Using 2-Nitro-5-Thiocyanobenzoic Acid and by Mismatch Analysis of cDNA HeteroduplexesMatrix, 1990
- Detection of point mutations in type I collagen by RNase digestion of RNA/RNA hybridsNucleic Acids Research, 1990
- Osteogenesis imperfecta. The position of substitution for glycine by cysteine in the triple helical domain of the pro alpha 1(I) chains of type I collagen determines the clinical phenotype.Journal of Clinical Investigation, 1989
- Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell AnemiaScience, 1985